HistoRx Receives $2,605,245 New Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    300 George Street New Haven, CT 06511
  • Company Description
    HistoRx has commercialized a technology originally developed at Yale Medical School used in the development of targeted drug therapies which are driving the evolution of personalized medicine. The Company’s new generation of predictive companion diagnostic tests can rapidly identify, validate and spatially map proteomic biomarkers in tissue samples, and translate these results into practical clinical applications for the treatment of breast cancer and other diseases.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. Amount may include options, warrants or other rights to acquire other securities. SEC regulatory filing.
  • M&A Terms
  • Venture Investor

Trending on Xconomy